New analysis of MYSTIC trial of Imfinzi monotherapy or Imfinzi + tremelimumab was presented at the ESMO Immuno-Oncology Congress- AstraZeneca

Added

In a full analysis of the MYSTIC study of Imfinzi (durvalumab) monotherapy or Imfinzi + tremelimumab which was presented at the ESMO Immuno-Oncology 2018 congress in Geneva ,Naiyer Rizvi of the Columbia University Medical Center in New York who was study author, noted that while not reaching statistical significance, Imfinzi monotherapy gave a clinically meaningful median OS improvement of 16.3 months compared to 12.9 months with chemotherapy in patients with 25% or greater PD-L1 expression.

Moreover an exploratory analysis which examined survival according to the biomarker of high or low tumor mutational burden (TMB) in the blood – 16 or more mutations per megabase was defined as high and fewer than 16 as low. TMB evaluation was performed in more than 70% of patients, of whom 40% had high TMB and for those patients OS was 16.5 months with the Imfinzi/ tremelimumab combination versus 10.5 months with chemotherapy; OS with Imfinzi alone was 11 months.

The proportion of high TMB patients alive at two years was 39% with the combination, 30% with Imfinzi and 18% with chemotherapy, while in those with low TMB, OS was 8.5 months with Imfinzi plus tremelimumab, 12.2 months with Imfinzi and 11.6 months with chemotherapy.

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

The purpose of this phase III, randomized, open-label, comparative, multicenter, international study is to compare the efficacy and safety of brigatinib to that of crizotinib in ALK-positive locally advanced or metastatic NSCLC...

This is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed compared with treatment with cisplatin or...

This randomized Phase III, multicenter, open-label study is designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+nab-paclitaxel...

This is a study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab (MK-3475, KEYTRUDA®) in adults with first line metastatic squamous non-small cell lung cancer (NSCLC).

This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment...

Dyspnoea is described as difficult or laboured breathing and is a frequent symptom in advanced cancer patients, with the highest prevalence in lung cancer. Dyspnoea has been demonstrated to be one of the most distressing...

Primary lung cancer is the most common malignancy after non-melanocytic skin cancer, and the leading cause of human cancer deaths worldwide. These guidelines focus on diagnosis and personalised medicine...